Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Finished Goods (2016 - 2018)

Historic Finished Goods for Teva Pharmaceutical Industries (TEVJF) over the last 9 years, with Q4 2018 value amounting to $2.7 billion.

  • Teva Pharmaceutical Industries' Finished Goods fell 89.25% to $2.7 billion in Q4 2018 from the same period last year, while for Dec 2018 it was $2.7 billion, marking a year-over-year decrease of 89.25%. This contributed to the annual value of $2.7 billion for FY2018, which is 89.25% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Finished Goods stood at $2.7 billion for Q4 2018, which was down 89.25% from $2.7 billion recorded in Q3 2018.
  • In the past 5 years, Teva Pharmaceutical Industries' Finished Goods registered a high of $2.8 billion during Q4 2016, and its lowest value of $2.1 billion during Q4 2015.
  • For the 5-year period, Teva Pharmaceutical Industries' Finished Goods averaged around $2.6 billion, with its median value being $2.7 billion (2017).
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Finished Goods tumbled by 1164.78% in 2014, and later soared by 3814.63% in 2016.
  • Over the past 5 years, Teva Pharmaceutical Industries' Finished Goods (Quarter) stood at $2.3 billion in 2014, then dropped by 9.61% to $2.1 billion in 2015, then soared by 38.15% to $2.8 billion in 2016, then decreased by 5.05% to $2.7 billion in 2017, then decreased by 0.89% to $2.7 billion in 2018.
  • Its Finished Goods stands at $2.7 billion for Q4 2018, versus $2.7 billion for Q3 2018 and $2.7 billion for Q2 2018.